|
Tarceva® (erlotinib) Reimbursement
Tarceva® (erlotinib)
DINs 02269023 (150mg), 02269015 (100mg), 02269007 (25mg)
Roche Patient Assistance Program 1-888-748-8926
The Roche Patient Assistance Program will investigate reimbursement options for patients who have been prescribed Roche rheumatoid arthritis, oncology and hematology therapies. For oncologists or hematologists who wish to print off a Patient Enrollment Form, please click here.
Tarceva® is an eligible benefit through most private insurance plans, some provincial/ territorial drug benefit programs and federal drug plans. Please choose the appropriate drug plan/program from the sidebar menu for specific information on Tarceva® reimbursement.
Indication
Tarceva® (erlotinib) therapy is indicated as monotherapy for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior chemotherapy regimen, and whose EGFR expression status is positive or unknown. [see Clinical Trials section - Relation of Results to EGFR Protein Expression Status (as Determined by Immunohistochemistry)]
Tarceva® should be administered under the supervision of a qualified health professional who is experienced in the treatment and management of patients with cancer.
Tarceva® is contraindicated in patients with severe hypersensitivity to erlotinib or to any component of Tarceva®.
The most common adverse events with Tarceva® vs. placebo are rash (75% vs 17%), diarrhea (54% vs 18%), fatigue (52% vs 45%), anorexia (52% vs 38%), dyspnea (41% vs 35%), nausea (33% vs 24%), cough (33% vs 29%), and vomiting (23% vs 19%).
Gastrointestinal hemorrhage (2%) was seen in patients taking Tarceva®. Confounding factors included concomitant NSAID use and history of peptic ulcer disease. Interstitial lung disease (0.8%) was seen in each treatment arm.
Please consult the Tarceva® Product Monograph (click on Health Professional Information for the full product monograph) for complete information on patient selection, dosing, precautions and warnings.
Resources for Healthcare Professionals and Patients
Getting the most from your treatment with Tarceva®, A Guide for Patients
Getting the most from your treatment with Tarceva®, Tips on Caring for Your Skin
Lung Cancer Canada Web Site
® Trade-Mark of OSI Pharmaceuticals, Inc.,
Used under license
|
